As Korean hyaluronic acid dermal fillers have gained availability in European markets, aesthetic practitioners are increasingly comparing products like Revolax and Neuramis with established Western alternatives such as Juvederm. This professional overview addresses key clinical and practical considerations.
Cross-linking Technology
All major HA fillers use BDDE (1,4-butanediol diglycidyl ether) cross-linking to extend longevity. Korean fillers including Revolax and Neuramis use comparable cross-linking technology to Juvederm and other established Western brands. The key performance parameters — G' (elastic modulus), cohesivity, and viscosity — are tuned through cross-linking density and HA concentration.
Revolax Deep vs Juvederm Ultra Plus
Revolax Deep (24mg/ml, Across Corp.) is positioned comparably to Juvederm Ultra Plus for deep tissue applications including nasolabial folds and chin augmentation. Both products are CE marked, contain lidocaine, and target 12–18 month duration. The primary clinical distinction practitioners note is a slightly firmer gel with Revolax, which may provide additional lifting force in some applications.
Neuramis Deep vs Juvederm Voluma
Neuramis Deep, using Medytox's SHAPE technology, produces a smooth, homogeneous gel with excellent flow properties through the needle. It is comparable to mid-range Juvederm products for moderate-to-severe correction. Juvederm Voluma's Vycross technology creates a more cohesive product specifically designed for structural volumisation, where it maintains a distinct positioning.
Cost and Value
Korean fillers offer a significant cost advantage compared to branded Western alternatives. For high-volume practices, the economics are compelling — comparable clinical results at a lower cost per syringe.